Back

SGO 2024 - Society of Gynecologic Oncology Annual Meeting on Women’s Cancer 2024

Mar 16 - Mar 18, 2024 | San DiegoCAUS

LARVOL is not affiliated with Society of Gynecologic Oncology Annual Meeting on Women’s Cancer 2024 and all trademarks, logos, and brand names are property of their respective owners

Showing 8 titles linked to Trials

Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: biomarker and subgroup analyses from the cervical, endometrial, and ovarian cancer cohorts of the DESTINY-PanTumor02 study

  • Live, Plenary

Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

  • Live, Plenary

Patient-Reported Outcomes from the Phase 3, Randomized, Double-Blind, Placebo-Controlled ENGOT-cx11/GOG 3047/KEYNOTE-A18 Study of Pembrolizumab Plus Concurrent Chemoradiotherapy (CCRT) in Patients With High-Risk Locally Advanced Cervical Can

  • Live, Plenary

Patient-Reported Outcome Results from Phase III MIRASOL Trial of mirvetuximab soravtansine vs. Investigator’s Choice of Chemotherapy in FRα Positive Platinum-resistant Ovarian Cancer

  • Live, Plenary

A PHASE II/III STUDY OF CEDIRANIB AND OLAPARIB COMBINATION COMPARED TO CEDIRANIB OR OLAPARIB ALONE, OR STANDARD OF CARE CHEMOTHERAPY IN PLATINUM-RESISTANT OVARIAN CANCER (NRG-GY005)

  • Live, Plenary

Anlotinib combined with carboplatin/paclitaxel and maintenance anlotinib as front-line treatment for newly diagnosed advanced ovarian cancer: A phase II, single-arm, multicenter study (ALTER-GO-010)

  • Live, Poster

Response to Treatment with nab-Sirolimus in Patients with Perivascular Epithelioid Cell Sarcoma (PEComa) of Gynecologic or Peritoneal Origin: Subgroup Analysis from AMPECT

  • Plenary

Overall survival in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY

  • Live, Plenary